Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > News out on Goblet trial with Merck

<< Previous

Bullboard Posts

Next >>

Comment by Kswdeluxon Nov 04, 2021 4:19am

184 Views

Post# 34085349

RE:RE:RE:RE:News out on Goblet trial with Merck

Interesting point, I had not given ANY thought at all to a CAR-T pharma buying them out. Just figured that CAR-T was still so far out there, as they have only come to the CAR-T realization in mice with the Mayo Clinic. But an interesting thought.

But then again, the Mayo clinic study did show that they actually KILLED the cancer is mice.

That is significant!

Is it significant enough at this time to step up and buyout ????

Interesting thought.

<< Previous

Bullboard Posts

Next >>

A Look into the Future of Chronic Pain Management